{"kind":"drive#fileList","files":[{"kind":"drive#file","id":"1V3lTRxLaunchPlanH1_2026_xyz12345AbCdEfGhIjKlMn","name":"Zenvara US Launch Plan — Year 1","mimeType":"application/vnd.google-apps.document","description":"Launch sequencing assumes Q2 formulary parity at top-3 PBMs. Field deployment at 142 reps across 6 regions.","category":"launch-tracking","ownerRole":"VP Commercial","createdTime":"2026-01-05T08:00:00.000Z","modifiedTime":"2025-04-28T14:21:00.000Z","modifiedByMeTime":"2025-04-28T14:21:00.000Z","viewedByMeTime":"2025-04-28T14:21:00.000Z","owners":[{"displayName":"Dana Park","emailAddress":"dana.park@pharma-team.example","kind":"drive#user","photoLink":"https://avatars.example/dana.park@pharma-team.example_192.png"}],"lastModifyingUser":{"displayName":"Dana Park","emailAddress":"dana.park@pharma-team.example","kind":"drive#user"},"parents":["0BPharmaTeamRootFolder12345678901234"],"webViewLink":"https://docs.google.com/document/d/1V3lTRxLaunchPlanH1_2026_xyz12345AbCdEfGhIjKlMn/edit","iconLink":"https://drive-thirdparty.googleusercontent.com/16/type/application/vnd.google-apps.document","shared":true,"starred":false,"trashed":false,"size":"70048","version":"47","headRevisionId":"rev-1V3lTRxLaunc","permissions":[{"id":"dana.park@pharma-team.example-owner","kind":"drive#permission","type":"user","role":"owner","emailAddress":"dana.park@pharma-team.example","displayName":"Dana Park"},{"id":"pharma-team-domain","kind":"drive#permission","type":"domain","role":"writer","domain":"pharma-team.example","displayName":"Pharma Team"}],"capabilities":{"canEdit":true,"canComment":true,"canShare":true}},{"kind":"drive#file","id":"1A2WeeklyLaunchTrackerWK19_abc456DefGhIjKlMnOpQ","name":"Weekly Launch Tracker — WK19","mimeType":"application/vnd.google-apps.document","description":"WK19 NBRx -14.1% in Northeast — UHC PA latency now the dominant gap-to-plan driver.","category":"launch-tracking","ownerRole":"Launch Excellence Lead","createdTime":"2026-01-05T08:00:00.000Z","modifiedTime":"2026-05-11T10:30:00.000Z","modifiedByMeTime":"2026-05-11T10:30:00.000Z","viewedByMeTime":"2026-05-11T10:30:00.000Z","owners":[{"displayName":"Marco Reyes","emailAddress":"marco.reyes@pharma-team.example","kind":"drive#user","photoLink":"https://avatars.example/marco.reyes@pharma-team.example_192.png"}],"lastModifyingUser":{"displayName":"Marco Reyes","emailAddress":"marco.reyes@pharma-team.example","kind":"drive#user"},"parents":["0BPharmaTeamRootFolder12345678901234"],"webViewLink":"https://docs.google.com/document/d/1A2WeeklyLaunchTrackerWK19_abc456DefGhIjKlMnOpQ/edit","iconLink":"https://drive-thirdparty.googleusercontent.com/16/type/application/vnd.google-apps.document","shared":true,"starred":false,"trashed":false,"size":"47480","version":"47","headRevisionId":"rev-1A2WeeklyLau","permissions":[{"id":"marco.reyes@pharma-team.example-owner","kind":"drive#permission","type":"user","role":"owner","emailAddress":"marco.reyes@pharma-team.example","displayName":"Marco Reyes"},{"id":"pharma-team-domain","kind":"drive#permission","type":"domain","role":"writer","domain":"pharma-team.example","displayName":"Pharma Team"}],"capabilities":{"canEdit":true,"canComment":true,"canShare":true}},{"kind":"drive#file","id":"1B5FieldForceActivityPlaybook32_def789GhIjKlMnOpQ","name":"Field Force Activity Playbook v3.2","mimeType":"application/vnd.google-apps.document","description":"Tier 1 HCPs require 2x reach/quarter with peer-to-peer + MSL touch. Replaces v3.1 RTE cadence after Q1 effectiveness review.","category":"launch-tracking","ownerRole":"Sr Director, Sales Ops","createdTime":"2026-01-05T08:00:00.000Z","modifiedTime":"2026-04-29T16:45:00.000Z","modifiedByMeTime":"2026-04-29T16:45:00.000Z","viewedByMeTime":"2026-04-29T16:45:00.000Z","owners":[{"displayName":"Ben Ortiz","emailAddress":"ben.ortiz@pharma-team.example","kind":"drive#user","photoLink":"https://avatars.example/ben.ortiz@pharma-team.example_192.png"}],"lastModifyingUser":{"displayName":"Ben Ortiz","emailAddress":"ben.ortiz@pharma-team.example","kind":"drive#user"},"parents":["0BPharmaTeamRootFolder12345678901234"],"webViewLink":"https://docs.google.com/document/d/1B5FieldForceActivityPlaybook32_def789GhIjKlMnOpQ/edit","iconLink":"https://drive-thirdparty.googleusercontent.com/16/type/application/vnd.google-apps.document","shared":true,"starred":false,"trashed":false,"size":"65856","version":"47","headRevisionId":"rev-1B5FieldForc","permissions":[{"id":"ben.ortiz@pharma-team.example-owner","kind":"drive#permission","type":"user","role":"owner","emailAddress":"ben.ortiz@pharma-team.example","displayName":"Ben Ortiz"},{"id":"pharma-team-domain","kind":"drive#permission","type":"domain","role":"writer","domain":"pharma-team.example","displayName":"Pharma Team"}],"capabilities":{"canEdit":true,"canComment":true,"canShare":true}},{"kind":"drive#file","id":"1C9NortheastDistrictPerfApr2026_ghi321JkLmNoPqRsTu","name":"Northeast District Performance Review — Apr 2026","mimeType":"application/vnd.google-apps.document","description":"Boston and NYC tracking 112% to plan; Philadelphia at 84% pending two large IDN pull-throughs. Two open territories filling June 1.","category":"launch-tracking","ownerRole":"Regional Sales Director","createdTime":"2026-01-05T08:00:00.000Z","modifiedTime":"2026-05-06T11:30:00.000Z","modifiedByMeTime":"2026-05-06T11:30:00.000Z","viewedByMeTime":"2026-05-06T11:30:00.000Z","owners":[{"displayName":"Lila Chen","emailAddress":"lila.chen@pharma-team.example","kind":"drive#user","photoLink":"https://avatars.example/lila.chen@pharma-team.example_192.png"}],"lastModifyingUser":{"displayName":"Lila Chen","emailAddress":"lila.chen@pharma-team.example","kind":"drive#user"},"parents":["0BPharmaTeamRootFolder12345678901234"],"webViewLink":"https://docs.google.com/document/d/1C9NortheastDistrictPerfApr2026_ghi321JkLmNoPqRsTu/edit","iconLink":"https://drive-thirdparty.googleusercontent.com/16/type/application/vnd.google-apps.document","shared":true,"starred":false,"trashed":false,"size":"45152","version":"47","headRevisionId":"rev-1C9Northeast","permissions":[{"id":"lila.chen@pharma-team.example-owner","kind":"drive#permission","type":"user","role":"owner","emailAddress":"lila.chen@pharma-team.example","displayName":"Lila Chen"},{"id":"pharma-team-domain","kind":"drive#permission","type":"domain","role":"writer","domain":"pharma-team.example","displayName":"Pharma Team"}],"capabilities":{"canEdit":true,"canComment":true,"canShare":true}},{"kind":"drive#file","id":"1D2PayerLandscapeBrief2026_jkl654MnOpQrStUvWxYz","name":"2026 US Payer Landscape Brief — Zenvara","mimeType":"application/vnd.google-apps.document","description":"Covers top 25 commercial plans + Medicare Part D. Net price erosion modeled at 4-6% post-IRA. UHC remains highest-leverage negotiation.","category":"market-access","ownerRole":"Sr Director, Market Access","createdTime":"2026-01-05T08:00:00.000Z","modifiedTime":"2026-05-08T10:00:00.000Z","modifiedByMeTime":"2026-05-08T10:00:00.000Z","viewedByMeTime":"2026-05-08T10:00:00.000Z","owners":[{"displayName":"Aisha Bello","emailAddress":"aisha.bello@pharma-team.example","kind":"drive#user","photoLink":"https://avatars.example/aisha.bello@pharma-team.example_192.png"}],"lastModifyingUser":{"displayName":"Aisha Bello","emailAddress":"aisha.bello@pharma-team.example","kind":"drive#user"},"parents":["0BPharmaTeamRootFolder12345678901234"],"webViewLink":"https://docs.google.com/document/d/1D2PayerLandscapeBrief2026_jkl654MnOpQrStUvWxYz/edit","iconLink":"https://drive-thirdparty.googleusercontent.com/16/type/application/vnd.google-apps.document","shared":true,"starred":false,"trashed":false,"size":"60688","version":"47","headRevisionId":"rev-1D2PayerLand","permissions":[{"id":"aisha.bello@pharma-team.example-owner","kind":"drive#permission","type":"user","role":"owner","emailAddress":"aisha.bello@pharma-team.example","displayName":"Aisha Bello"},{"id":"pharma-team-domain","kind":"drive#permission","type":"domain","role":"writer","domain":"pharma-team.example","displayName":"Pharma Team"}],"capabilities":{"canEdit":true,"canComment":true,"canShare":true}},{"kind":"drive#file","id":"1E7FormularyWinLossLog2026_mno987PqRsTuVwXyZ1234","name":"Formulary Win/Loss Log — YTD 2026","mimeType":"application/vnd.google-apps.document","description":"Cigna win (+14.1M lives) this week. YTD net change: +23.5M lives across 18 wins, offset by 2 losses + 1 step-edit imposition.","category":"market-access","ownerRole":"Payer Account Lead","createdTime":"2026-01-05T08:00:00.000Z","modifiedTime":"2026-05-15T09:00:00.000Z","modifiedByMeTime":"2026-05-15T09:00:00.000Z","viewedByMeTime":"2026-05-15T09:00:00.000Z","owners":[{"displayName":"Tony Alvarez","emailAddress":"tony.alvarez@pharma-team.example","kind":"drive#user","photoLink":"https://avatars.example/tony.alvarez@pharma-team.example_192.png"}],"lastModifyingUser":{"displayName":"Tony Alvarez","emailAddress":"tony.alvarez@pharma-team.example","kind":"drive#user"},"parents":["0BPharmaTeamRootFolder12345678901234"],"webViewLink":"https://docs.google.com/document/d/1E7FormularyWinLossLog2026_mno987PqRsTuVwXyZ1234/edit","iconLink":"https://drive-thirdparty.googleusercontent.com/16/type/application/vnd.google-apps.document","shared":true,"starred":false,"trashed":false,"size":"40592","version":"47","headRevisionId":"rev-1E7Formulary","permissions":[{"id":"tony.alvarez@pharma-team.example-owner","kind":"drive#permission","type":"user","role":"owner","emailAddress":"tony.alvarez@pharma-team.example","displayName":"Tony Alvarez"},{"id":"pharma-team-domain","kind":"drive#permission","type":"domain","role":"writer","domain":"pharma-team.example","displayName":"Pharma Team"}],"capabilities":{"canEdit":true,"canComment":true,"canShare":true}},{"kind":"drive#file","id":"1F1PayerObjectionPlaybook_pqr543StUvWxYz12345Abc","name":"Payer Objection Handling Playbook","mimeType":"application/vnd.google-apps.document","description":"Top objection remains budget impact at year 2. Approved counter-evidence: BIM v4, real-world Optum claims cohort (n=12,400).","category":"market-access","ownerRole":"Market Access Strategy","createdTime":"2026-01-05T08:00:00.000Z","modifiedTime":"2026-03-22T08:15:00.000Z","modifiedByMeTime":"2026-03-22T08:15:00.000Z","viewedByMeTime":"2026-03-22T08:15:00.000Z","owners":[{"displayName":"Aisha Bello","emailAddress":"aisha.bello@pharma-team.example","kind":"drive#user","photoLink":"https://avatars.example/aisha.bello@pharma-team.example_192.png"}],"lastModifyingUser":{"displayName":"Aisha Bello","emailAddress":"aisha.bello@pharma-team.example","kind":"drive#user"},"parents":["0BPharmaTeamRootFolder12345678901234"],"webViewLink":"https://docs.google.com/document/d/1F1PayerObjectionPlaybook_pqr543StUvWxYz12345Abc/edit","iconLink":"https://drive-thirdparty.googleusercontent.com/16/type/application/vnd.google-apps.document","shared":true,"starred":false,"trashed":false,"size":"53856","version":"47","headRevisionId":"rev-1F1PayerObje","permissions":[{"id":"aisha.bello@pharma-team.example-owner","kind":"drive#permission","type":"user","role":"owner","emailAddress":"aisha.bello@pharma-team.example","displayName":"Aisha Bello"},{"id":"pharma-team-domain","kind":"drive#permission","type":"domain","role":"writer","domain":"pharma-team.example","displayName":"Pharma Team"}],"capabilities":{"canEdit":true,"canComment":true,"canShare":true}},{"kind":"drive#file","id":"1G6IRAImpactAnalysis2027_stu876VwXyZ123AbCdEfGhI","name":"IRA Negotiation Impact Analysis — Zenvara 2032+ Eligibility","mimeType":"application/vnd.google-apps.document","description":"Zenvara crosses small-molecule 7-year threshold January 2032. Modeled MFP outcomes 38-52% off WAC. NPV impact -$1.2B to -$0.4B over 5 years.","category":"market-access","ownerRole":"HEOR Director","createdTime":"2026-01-05T08:00:00.000Z","modifiedTime":"2026-05-11T13:22:00.000Z","modifiedByMeTime":"2026-05-11T13:22:00.000Z","viewedByMeTime":"2026-05-11T13:22:00.000Z","owners":[{"displayName":"Sara Lindqvist","emailAddress":"sara.lindqvist@pharma-team.example","kind":"drive#user","photoLink":"https://avatars.example/sara.lindqvist@pharma-team.example_192.png"}],"lastModifyingUser":{"displayName":"Sara Lindqvist","emailAddress":"sara.lindqvist@pharma-team.example","kind":"drive#user"},"parents":["0BPharmaTeamRootFolder12345678901234"],"webViewLink":"https://docs.google.com/document/d/1G6IRAImpactAnalysis2027_stu876VwXyZ123AbCdEfGhI/edit","iconLink":"https://drive-thirdparty.googleusercontent.com/16/type/application/vnd.google-apps.document","shared":true,"starred":false,"trashed":false,"size":"46936","version":"47","headRevisionId":"rev-1G6IRAImpact","permissions":[{"id":"sara.lindqvist@pharma-team.example-owner","kind":"drive#permission","type":"user","role":"owner","emailAddress":"sara.lindqvist@pharma-team.example","displayName":"Sara Lindqvist"},{"id":"pharma-team-domain","kind":"drive#permission","type":"domain","role":"writer","domain":"pharma-team.example","displayName":"Pharma Team"}],"capabilities":{"canEdit":true,"canComment":true,"canShare":true}},{"kind":"drive#file","id":"1H3NICESubmissionPlanVeltarix_vwx109XyZ123AbCdEfGh","name":"NICE STA Submission Plan — Veltarix","mimeType":"application/vnd.google-apps.document","description":"Submission deadline 2026-09-01. ICER threshold strategy assumes £28k/QALY base case. 4 blocker gaps remaining, biggest is long-term durability extrapolation (14mo to close).","category":"submissions","ownerRole":"HTA Lead, UK","createdTime":"2026-01-05T08:00:00.000Z","modifiedTime":"2026-05-13T17:00:00.000Z","modifiedByMeTime":"2026-05-13T17:00:00.000Z","viewedByMeTime":"2026-05-13T17:00:00.000Z","owners":[{"displayName":"Sara Lindqvist","emailAddress":"sara.lindqvist@pharma-team.example","kind":"drive#user","photoLink":"https://avatars.example/sara.lindqvist@pharma-team.example_192.png"}],"lastModifyingUser":{"displayName":"Sara Lindqvist","emailAddress":"sara.lindqvist@pharma-team.example","kind":"drive#user"},"parents":["0BPharmaTeamRootFolder12345678901234"],"webViewLink":"https://docs.google.com/document/d/1H3NICESubmissionPlanVeltarix_vwx109XyZ123AbCdEfGh/edit","iconLink":"https://drive-thirdparty.googleusercontent.com/16/type/application/vnd.google-apps.document","shared":true,"starred":false,"trashed":false,"size":"60128","version":"47","headRevisionId":"rev-1H3NICESubmi","permissions":[{"id":"sara.lindqvist@pharma-team.example-owner","kind":"drive#permission","type":"user","role":"owner","emailAddress":"sara.lindqvist@pharma-team.example","displayName":"Sara Lindqvist"},{"id":"pharma-team-domain","kind":"drive#permission","type":"domain","role":"writer","domain":"pharma-team.example","displayName":"Pharma Team"}],"capabilities":{"canEdit":true,"canComment":true,"canShare":true}},{"kind":"drive#file","id":"1I8EvidenceDossierIndexMaster_yzA987BCdEfGhIjKlMno","name":"Evidence Dossier Index — Global Master","mimeType":"application/vnd.google-apps.document","description":"47 evidence assets mapped across NICE, G-BA, HAS, CADTH, JCA. Module 4 economic models versioned in /econ/v6/.","category":"submissions","ownerRole":"Global Value & Access","createdTime":"2026-01-05T08:00:00.000Z","modifiedTime":"2026-05-09T07:50:00.000Z","modifiedByMeTime":"2026-05-09T07:50:00.000Z","viewedByMeTime":"2026-05-09T07:50:00.000Z","owners":[{"displayName":"Sara Lindqvist","emailAddress":"sara.lindqvist@pharma-team.example","kind":"drive#user","photoLink":"https://avatars.example/sara.lindqvist@pharma-team.example_192.png"}],"lastModifyingUser":{"displayName":"Sara Lindqvist","emailAddress":"sara.lindqvist@pharma-team.example","kind":"drive#user"},"parents":["0BPharmaTeamRootFolder12345678901234"],"webViewLink":"https://docs.google.com/document/d/1I8EvidenceDossierIndexMaster_yzA987BCdEfGhIjKlMno/edit","iconLink":"https://drive-thirdparty.googleusercontent.com/16/type/application/vnd.google-apps.document","shared":true,"starred":false,"trashed":false,"size":"53056","version":"47","headRevisionId":"rev-1I8EvidenceD","permissions":[{"id":"sara.lindqvist@pharma-team.example-owner","kind":"drive#permission","type":"user","role":"owner","emailAddress":"sara.lindqvist@pharma-team.example","displayName":"Sara Lindqvist"},{"id":"pharma-team-domain","kind":"drive#permission","type":"domain","role":"writer","domain":"pharma-team.example","displayName":"Pharma Team"}],"capabilities":{"canEdit":true,"canComment":true,"canShare":true}},{"kind":"drive#file","id":"1J4HTAEvidenceGapReportQ2_bcd654EfGhIjKlMnOpQrSt","name":"HTA Evidence Gap Report — Q2 2026","mimeType":"application/vnd.google-apps.document","description":"Three blocker gaps remain across the global submission portfolio: ITC vs SoC, long-term durability, renal subgroup. Combined estimated time to close: 18 months.","category":"submissions","ownerRole":"HEOR Director","createdTime":"2026-01-05T08:00:00.000Z","modifiedTime":"2026-05-07T19:30:00.000Z","modifiedByMeTime":"2026-05-07T19:30:00.000Z","viewedByMeTime":"2026-05-07T19:30:00.000Z","owners":[{"displayName":"Sara Lindqvist","emailAddress":"sara.lindqvist@pharma-team.example","kind":"drive#user","photoLink":"https://avatars.example/sara.lindqvist@pharma-team.example_192.png"}],"lastModifyingUser":{"displayName":"Sara Lindqvist","emailAddress":"sara.lindqvist@pharma-team.example","kind":"drive#user"},"parents":["0BPharmaTeamRootFolder12345678901234"],"webViewLink":"https://docs.google.com/document/d/1J4HTAEvidenceGapReportQ2_bcd654EfGhIjKlMnOpQrSt/edit","iconLink":"https://drive-thirdparty.googleusercontent.com/16/type/application/vnd.google-apps.document","shared":true,"starred":false,"trashed":false,"size":"33912","version":"47","headRevisionId":"rev-1J4HTAEviden","permissions":[{"id":"sara.lindqvist@pharma-team.example-owner","kind":"drive#permission","type":"user","role":"owner","emailAddress":"sara.lindqvist@pharma-team.example","displayName":"Sara Lindqvist"},{"id":"pharma-team-domain","kind":"drive#permission","type":"domain","role":"writer","domain":"pharma-team.example","displayName":"Pharma Team"}],"capabilities":{"canEdit":true,"canComment":true,"canShare":true}},{"kind":"drive#file","id":"1K7GBADossier2024Lessons_efg321HiJkLmNoPqRsTuVwX","name":"2024 G-BA Dossier — Module 4 Lessons Learned","mimeType":"application/vnd.google-apps.document","description":"IQWiG flagged comparator selection (docetaxel) as inappropriate vs G-BA-defined ZVT (pembrolizumab monotherapy). Benefit assessment downgraded to 'non-quantifiable'.","category":"submissions","ownerRole":"HTA Lead, DACH","createdTime":"2026-01-05T08:00:00.000Z","modifiedTime":"2024-11-04T12:00:00.000Z","modifiedByMeTime":"2024-11-04T12:00:00.000Z","viewedByMeTime":"2024-11-04T12:00:00.000Z","owners":[{"displayName":"Sara Lindqvist","emailAddress":"sara.lindqvist@pharma-team.example","kind":"drive#user","photoLink":"https://avatars.example/sara.lindqvist@pharma-team.example_192.png"}],"lastModifyingUser":{"displayName":"Sara Lindqvist","emailAddress":"sara.lindqvist@pharma-team.example","kind":"drive#user"},"parents":["0BPharmaTeamRootFolder12345678901234"],"webViewLink":"https://docs.google.com/document/d/1K7GBADossier2024Lessons_efg321HiJkLmNoPqRsTuVwX/edit","iconLink":"https://drive-thirdparty.googleusercontent.com/16/type/application/vnd.google-apps.document","shared":true,"starred":false,"trashed":false,"size":"45592","version":"47","headRevisionId":"rev-1K7GBADossie","permissions":[{"id":"sara.lindqvist@pharma-team.example-owner","kind":"drive#permission","type":"user","role":"owner","emailAddress":"sara.lindqvist@pharma-team.example","displayName":"Sara Lindqvist"},{"id":"pharma-team-domain","kind":"drive#permission","type":"domain","role":"writer","domain":"pharma-team.example","displayName":"Pharma Team"}],"capabilities":{"canEdit":true,"canComment":true,"canShare":true}},{"kind":"drive#file","id":"1L9ASCO2026Readout_hij098KlMnOpQrStUvWxYz12345","name":"ASCO 2026 Readout — Competitive Implications for Zenvara","mimeType":"application/vnd.google-apps.document","description":"Competitor X (BMS CheckMate-X) Ph3 missed primary PFS endpoint (HR 0.91, p=0.18). Reduces near-term 2L threat.","category":"competitive-intel","ownerRole":"Competitive Intel Lead","createdTime":"2026-01-05T08:00:00.000Z","modifiedTime":"2026-05-14T18:30:00.000Z","modifiedByMeTime":"2026-05-14T18:30:00.000Z","viewedByMeTime":"2026-05-14T18:30:00.000Z","owners":[{"displayName":"Jordan Patel","emailAddress":"jordan.patel@pharma-team.example","kind":"drive#user","photoLink":"https://avatars.example/jordan.patel@pharma-team.example_192.png"}],"lastModifyingUser":{"displayName":"Jordan Patel","emailAddress":"jordan.patel@pharma-team.example","kind":"drive#user"},"parents":["0BPharmaTeamRootFolder12345678901234"],"webViewLink":"https://docs.google.com/document/d/1L9ASCO2026Readout_hij098KlMnOpQrStUvWxYz12345/edit","iconLink":"https://drive-thirdparty.googleusercontent.com/16/type/application/vnd.google-apps.document","shared":true,"starred":false,"trashed":false,"size":"46944","version":"47","headRevisionId":"rev-1L9ASCO2026R","permissions":[{"id":"jordan.patel@pharma-team.example-owner","kind":"drive#permission","type":"user","role":"owner","emailAddress":"jordan.patel@pharma-team.example","displayName":"Jordan Patel"},{"id":"pharma-team-domain","kind":"drive#permission","type":"domain","role":"writer","domain":"pharma-team.example","displayName":"Pharma Team"}],"capabilities":{"canEdit":true,"canComment":true,"canShare":true}},{"kind":"drive#file","id":"1M2KOLAdvBoardApr2026_klm765NoPqRsTuVwXyZ12AbC","name":"KOL Advisory Board — Apr 2026 Synthesis","mimeType":"application/vnd.google-apps.document","description":"Eight KOLs across US/EU. Consensus: sequencing question post-progression remains unresolved; demand for head-to-head data is loudest signal.","category":"competitive-intel","ownerRole":"Medical Affairs Director","createdTime":"2026-01-05T08:00:00.000Z","modifiedTime":"2026-05-02T09:11:00.000Z","modifiedByMeTime":"2026-05-02T09:11:00.000Z","viewedByMeTime":"2026-05-02T09:11:00.000Z","owners":[{"displayName":"Karen Wu, PharmD","emailAddress":"karen.wu@pharma-team.example","kind":"drive#user","photoLink":"https://avatars.example/karen.wu@pharma-team.example_192.png"}],"lastModifyingUser":{"displayName":"Karen Wu, PharmD","emailAddress":"karen.wu@pharma-team.example","kind":"drive#user"},"parents":["0BPharmaTeamRootFolder12345678901234"],"webViewLink":"https://docs.google.com/document/d/1M2KOLAdvBoardApr2026_klm765NoPqRsTuVwXyZ12AbC/edit","iconLink":"https://drive-thirdparty.googleusercontent.com/16/type/application/vnd.google-apps.document","shared":true,"starred":false,"trashed":false,"size":"64728","version":"47","headRevisionId":"rev-1M2KOLAdvBoa","permissions":[{"id":"karen.wu@pharma-team.example-owner","kind":"drive#permission","type":"user","role":"owner","emailAddress":"karen.wu@pharma-team.example","displayName":"Karen Wu, PharmD"},{"id":"pharma-team-domain","kind":"drive#permission","type":"domain","role":"writer","domain":"pharma-team.example","displayName":"Pharma Team"}],"capabilities":{"canEdit":true,"canComment":true,"canShare":true}},{"kind":"drive#file","id":"1N5CompetitorMonitorTracker_nop432QrStUvWxYz12AbCd","name":"Competitor Monitoring Tracker — Zenvara Class","mimeType":"application/vnd.google-apps.document","description":"Six assets tracked across Phase 2/3. CheckMate-X failed (May 14); AbbVie pipeline asset entered Ph3 enrollment 2026-04-18.","category":"competitive-intel","ownerRole":"Competitive Intel Analyst","createdTime":"2026-01-05T08:00:00.000Z","modifiedTime":"2026-05-15T18:00:00.000Z","modifiedByMeTime":"2026-05-15T18:00:00.000Z","viewedByMeTime":"2026-05-15T18:00:00.000Z","owners":[{"displayName":"Jordan Patel","emailAddress":"jordan.patel@pharma-team.example","kind":"drive#user","photoLink":"https://avatars.example/jordan.patel@pharma-team.example_192.png"}],"lastModifyingUser":{"displayName":"Jordan Patel","emailAddress":"jordan.patel@pharma-team.example","kind":"drive#user"},"parents":["0BPharmaTeamRootFolder12345678901234"],"webViewLink":"https://docs.google.com/document/d/1N5CompetitorMonitorTracker_nop432QrStUvWxYz12AbCd/edit","iconLink":"https://drive-thirdparty.googleusercontent.com/16/type/application/vnd.google-apps.document","shared":true,"starred":false,"trashed":false,"size":"42240","version":"47","headRevisionId":"rev-1N5Competito","permissions":[{"id":"jordan.patel@pharma-team.example-owner","kind":"drive#permission","type":"user","role":"owner","emailAddress":"jordan.patel@pharma-team.example","displayName":"Jordan Patel"},{"id":"pharma-team-domain","kind":"drive#permission","type":"domain","role":"writer","domain":"pharma-team.example","displayName":"Pharma Team"}],"capabilities":{"canEdit":true,"canComment":true,"canShare":true}},{"kind":"drive#file","id":"1O8CongressCalendar2026_qrs109TuVwXyZ12AbCdEfGhI","name":"2026 Congress Calendar & Coverage Plan","mimeType":"application/vnd.google-apps.document","description":"Priority: ASCO, ESMO, AHA, ACR. 14 abstracts submitted; symposium slots confirmed at ESMO and ACR.","category":"competitive-intel","ownerRole":"Medical Communications","createdTime":"2026-01-05T08:00:00.000Z","modifiedTime":"2026-04-11T14:00:00.000Z","modifiedByMeTime":"2026-04-11T14:00:00.000Z","viewedByMeTime":"2026-04-11T14:00:00.000Z","owners":[{"displayName":"Karen Wu, PharmD","emailAddress":"karen.wu@pharma-team.example","kind":"drive#user","photoLink":"https://avatars.example/karen.wu@pharma-team.example_192.png"}],"lastModifyingUser":{"displayName":"Karen Wu, PharmD","emailAddress":"karen.wu@pharma-team.example","kind":"drive#user"},"parents":["0BPharmaTeamRootFolder12345678901234"],"webViewLink":"https://docs.google.com/document/d/1O8CongressCalendar2026_qrs109TuVwXyZ12AbCdEfGhI/edit","iconLink":"https://drive-thirdparty.googleusercontent.com/16/type/application/vnd.google-apps.document","shared":true,"starred":false,"trashed":false,"size":"44688","version":"47","headRevisionId":"rev-1O8CongressC","permissions":[{"id":"karen.wu@pharma-team.example-owner","kind":"drive#permission","type":"user","role":"owner","emailAddress":"karen.wu@pharma-team.example","displayName":"Karen Wu, PharmD"},{"id":"pharma-team-domain","kind":"drive#permission","type":"domain","role":"writer","domain":"pharma-team.example","displayName":"Pharma Team"}],"capabilities":{"canEdit":true,"canComment":true,"canShare":true}},{"kind":"drive#file","id":"1P12026CommercialPlan_rst876UvWxYz12AbCdEfGhIjK","name":"2026 Commercial Plan — Zenvara/Veltarix Franchise","mimeType":"application/vnd.google-apps.document","description":"Year-2 revenue plan $580M global (US $410M, EU $130M, RoW $40M). Reflects revised payer ramp and 78% formulary coverage by Q4.","category":"strategic","ownerRole":"VP Commercial","createdTime":"2026-01-05T08:00:00.000Z","modifiedTime":"2026-02-28T22:00:00.000Z","modifiedByMeTime":"2026-02-28T22:00:00.000Z","viewedByMeTime":"2026-02-28T22:00:00.000Z","owners":[{"displayName":"Dana Park","emailAddress":"dana.park@pharma-team.example","kind":"drive#user","photoLink":"https://avatars.example/dana.park@pharma-team.example_192.png"}],"lastModifyingUser":{"displayName":"Dana Park","emailAddress":"dana.park@pharma-team.example","kind":"drive#user"},"parents":["0BPharmaTeamRootFolder12345678901234"],"webViewLink":"https://docs.google.com/document/d/1P12026CommercialPlan_rst876UvWxYz12AbCdEfGhIjK/edit","iconLink":"https://drive-thirdparty.googleusercontent.com/16/type/application/vnd.google-apps.document","shared":true,"starred":false,"trashed":false,"size":"56016","version":"47","headRevisionId":"rev-1P12026Comme","permissions":[{"id":"dana.park@pharma-team.example-owner","kind":"drive#permission","type":"user","role":"owner","emailAddress":"dana.park@pharma-team.example","displayName":"Dana Park"},{"id":"pharma-team-domain","kind":"drive#permission","type":"domain","role":"writer","domain":"pharma-team.example","displayName":"Pharma Team"}],"capabilities":{"canEdit":true,"canComment":true,"canShare":true}},{"kind":"drive#file","id":"1Q4LifecycleMgmtRoadmap2026_uvw543XyZ12AbCdEfGhIjK","name":"Lifecycle Management Roadmap — 2026-2030","mimeType":"application/vnd.google-apps.document","description":"Three indication expansions (2L mCRC, adjuvant breast, pediatric AML). Subcutaneous reformulation gated to 2028 pending Ph1 PK bridging.","category":"strategic","ownerRole":"LCM Strategy Lead","createdTime":"2026-01-05T08:00:00.000Z","modifiedTime":"2026-04-22T11:00:00.000Z","modifiedByMeTime":"2026-04-22T11:00:00.000Z","viewedByMeTime":"2026-04-22T11:00:00.000Z","owners":[{"displayName":"Marco Reyes","emailAddress":"marco.reyes@pharma-team.example","kind":"drive#user","photoLink":"https://avatars.example/marco.reyes@pharma-team.example_192.png"}],"lastModifyingUser":{"displayName":"Marco Reyes","emailAddress":"marco.reyes@pharma-team.example","kind":"drive#user"},"parents":["0BPharmaTeamRootFolder12345678901234"],"webViewLink":"https://docs.google.com/document/d/1Q4LifecycleMgmtRoadmap2026_uvw543XyZ12AbCdEfGhIjK/edit","iconLink":"https://drive-thirdparty.googleusercontent.com/16/type/application/vnd.google-apps.document","shared":true,"starred":false,"trashed":false,"size":"49896","version":"47","headRevisionId":"rev-1Q4Lifecycle","permissions":[{"id":"marco.reyes@pharma-team.example-owner","kind":"drive#permission","type":"user","role":"owner","emailAddress":"marco.reyes@pharma-team.example","displayName":"Marco Reyes"},{"id":"pharma-team-domain","kind":"drive#permission","type":"domain","role":"writer","domain":"pharma-team.example","displayName":"Pharma Team"}],"capabilities":{"canEdit":true,"canComment":true,"canShare":true}}],"nextPageToken":null,"incompleteSearch":false}